GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSNKY) » Definitions » Buyback Yield %

Daiichinkyo Co (Daiichinkyo Co) Buyback Yield % : 0.00 (As of Apr. 28, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Daiichinkyo Co Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Daiichinkyo Co's current buyback yield was 0.00%.


Daiichinkyo Co Buyback Yield % Historical Data

The historical data trend for Daiichinkyo Co's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Buyback Yield % Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.64 - - -

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Daiichinkyo Co's Buyback Yield %

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Buyback Yield % falls into.



Daiichinkyo Co Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Daiichinkyo Co's Buyback Yield for the fiscal year that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.167 + 0) / 60995.675
=0.00%

Daiichinkyo Co's annualized Buyback Yield for the quarter that ended in Mar. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (-0.053 + 0) * 4 / 60995.675
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Mar. 2024) data.


Daiichinkyo Co Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (Daiichinkyo Co) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.